Cibus, Inc. Class A Common Stock (CBUS) Stock
Key stats
- Market cap
- $98.59M
- Price / Earnings ratio
- -1.1x
- EPS (TTM)
- -$1.63
- Volume
- Loading
- 52-week high
- $4.19
- 52-week low
- $1.09
Source: third-party data provider, as of October 17, 2026
Compare with CBUS
Recent news

Cibus (CBUS) Reports Q2 Loss, Misses Revenue Estimates
Cibus (CBUS) Reports Q2 Loss, Misses Revenue Estimates
CBUS

Cibus Q2 Earnings Call Highlights
Cibus Q2 Earnings Call Highlights
CBUS

Cibus (CBUS) Reports Q1 Loss, Beats Revenue Estimates
Cibus (CBUS) Reports Q1 Loss, Beats Revenue Estimates
CBUS

Cibus Q1 Earnings Call Highlights
Cibus Q1 Earnings Call Highlights
CBUS
Technical indicators
- RSI 14
- 31.22
- MACD 12/26/9
- -0.06
- EMA 9 of MACD
- -0.03
- MACD histogram
- -0.03
- SMA 50
- $1.62
- Price below SMA 50
- EMA 50
- $1.59
- Price below EMA 50
- SMA 200
- $1.88
- Price below SMA 200
- EMA 200
- $1.75
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 15, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Cibus (CBUS) Reports Q2 Loss, Misses Revenue Estimates
Cibus (CBUS) Reports Q2 Loss, Misses Revenue Estimates
CBUS

Cibus Q2 Earnings Call Highlights
Cibus Q2 Earnings Call Highlights
CBUS

Cibus (CBUS) Reports Q1 Loss, Beats Revenue Estimates
Cibus (CBUS) Reports Q1 Loss, Beats Revenue Estimates
CBUS

Cibus Q1 Earnings Call Highlights
Cibus Q1 Earnings Call Highlights
CBUS

Cibus (CBUS) Upgraded to Buy: What Does It Mean for the Stock?
Cibus (CBUS) Upgraded to Buy: What Does It Mean for the Stock?
CBUS

Cibus (CBUS) Reports Q4 Loss, Lags Revenue Estimates
Cibus (CBUS) Reports Q4 Loss, Lags Revenue Estimates
CBUS

5 REITs That Are Overleveraged
5 REITs That Are Overleveraged
CBUS
About Cibus, Inc. Class A Common Stock
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Craig Wichner | Chief Executive Officer | 1970 |
| Dr. Peter R. Beetham B.Sc., Ph.D. | Co-Founder, President & COO | 1963 |
| Mr. Cornelis Broos M.Sc. | Chief Financial Officer | 1972 |
| Dr. Gregory F. Gocal Ph.D. | Co-Founder, Chief Scientific Officer & Executive VP | 1969 |
| Mr. Rory Balfour Riggs M.B.A. | Co-Founder & Director | 1953 |
| Mr. Jason Stokes Esq., J.D. | Chief Administrative Officer, General Counsel & Corporate Secretary | 1971 |
| Ms. Rosa Cheuk Kim J.D. | Senior Vice President of Legal | — |
| Dr. Noel Sauer Ph.D. | Senior Vice President of Research | 1967 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 17, 2026
Technical indicators
- RSI 14
- 31.22
- MACD 12/26/9
- -0.06
- EMA 9 of MACD
- -0.03
- MACD histogram
- -0.03
- SMA 50
- $1.62
- Price below SMA 50
- EMA 50
- $1.59
- Price below EMA 50
- SMA 200
- $1.88
- Price below SMA 200
- EMA 200
- $1.75
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 15, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +13.2 | -46.6 | -27.5 | -0.7 | -6.8 | +35.9 | -14.3 | +3.2 | -20.9 |



